2-(9-methyl-2-phenyl-5H-[1,2,4]triazolo[5,1-a][2,7]naphthyridin-6-yl)acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(9-methyl-2-phenyl-5H-[1,2,4]triazolo[5,1-a][2,7]naphthyridin-6-yl)acetic acid
• 化学式: C₁₈H₁₆N₄O₂
• 分子量: 320.3
• InChiKey: PTPNGMWYDMTEND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  71.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
  申请人：The United States of America, Represented by the Secretary, Department of Health and Human Services

  公开号：EP2311806A2

  公开（公告）日：2011-04-20

  The present invention provides certain novel compounds, compositions, and a method of treating a mammal by blocking its adenosine receptors comprising administering at least one compound of the present invention. Examples of the present inventive compounds include certain flavonoids of formulae (I) and (II), wherein R1 to R4 are as defined in the description, and M is -CH (OH) -CH (R2) - or -C(OH)=C(R2)- and R1, R2 are as defined in the description; or dihydropyridines of formula (III), wherein R2 to R6 are as defined in the description; or pyridines of formula (IV), wherein R2 to R6 are as defined in the description, or triazoloquinazolines of formula (V), wherein R1 and R2 are as defined in the description; and their derivatives, or pharmaceutically acceptable salts thereof.

  本发明提供了某些新型化合物、组合物以及一种通过阻断哺乳动物的腺苷受体来治疗哺乳动物的方法，该方法包括施用至少一种本发明化合物。本发明化合物的实例包括某些式(I)和(II)的黄酮类化合物，其中R1至R4如说明中所定义，M为-CH(OH)-CH(R2)-或-C(OH)＝C(R2)-且R1、R2如说明中所定义；或式(III)的二氢吡啶类化合物，其中R2至R6如说明中所定义；或式（IV）的吡啶，其中 R2 至 R6 如说明书中定义；或式（V）的三唑并喹唑啉，其中 R1 和 R2 如说明书中定义；以及它们的衍生物或药学上可接受的盐。
• Methods for reducing intraocular pressure
  申请人：——

  公开号：US20030153626A1

  公开（公告）日：2003-08-14

  A method for decreasing intraocular pressure by administering an A 3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. These agents, by inhibiting influx or promoting efflux of aqueous humor, can be used to treat glaucoma.

  一种通过施用 A 3 亚型腺苷受体拮抗剂、钙调素拮抗剂或抗雌激素（如他莫昔芬）来降低眼压的方法。这些药物通过抑制房水的流入或促进房水的流出，可用于治疗青光眼。
• DIHYDROPYRIDINE-, PYRIDINE-, BENZOPYRAN- ONE- AND TRIAZOLOQUINAZOLINE DERIVATIVE, THEIR PREPARATION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：The United States of America, Represented by the Secretary, Department of Health and Human Services

  公开号：EP0885192B1

  公开（公告）日：2012-03-07
• EFFECTIVE DELIVERY OF CROSS-SPECIES A3 ADENOSINE-RECEPTOR ANTAGONISTS TO REDUCE INTRAOCULAR PRESSURE
  申请人：The Trustees of the University of Pennsylvania

  公开号：EP2076267A2

  公开（公告）日：2009-07-08
• Method of using vasoconstrictive agents during energy-based tissue therapy
  申请人：Podhajsky Ronald J.

  公开号：US20070208042A1

  公开（公告）日：2007-09-06

  A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy.